Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer

References

• Torre LA , BrayF, SiegelRL, FerlayJ, Lortet-TieulentJ, JemalA. Global cancer statistics, 2012. CA Cancer J. Clin.65(2), 87–108 (2015).
   PubMed Web of Science ®Google Scholar
• Timar J , KashoferK. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev.39(4), 1029–1038 (2020).
   PubMed Web of Science ®Google Scholar
• Ghimessy A , RadeczkyP, LaszloVet al. Current therapy of KRAS-mutant lung cancer. Cancer Metastasis Rev.39(4), 1159–1177 (2020).
   PubMed Web of Science ®Google Scholar
• Skoulidis F , LiBT, DyGKet al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med.384(25), 2371–2381 (2021).
   PubMed Web of Science ®Google Scholar
• Riely GJ , OuSHI, RybkinIet al. 99O_PR KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. J. Thorac. Oncol.16(Suppl. 4), S751–S752 (2021).
   Web of Science ®Google Scholar
• Nakajima EC , DreznerN, LiXet al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin. Cancer Res.28(8), 1482–1486 (2022).
   PubMed Web of Science ®Google Scholar
• Blair HA . Sotorasib: first approval. Drugs81(13), 1573–1579 (2021).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines version 3.2022 – non-small cell lung cancer. Available from: www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Lee CK , ManJ, LordSet al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol.4(2), 210–216 (2018).
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ , RizviH, BandlamudiCet al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann. Oncol.31(5), 599–608 (2020).
   PubMed Web of Science ®Google Scholar
• Herbst RS , LopesG, KowalskiDMet al. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042. Ann. Oncol.30, xi63–xi64 (2019).
   Web of Science ®Google Scholar
• Noordhof AL , DamhuisRaM, HendriksLELet al. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. Lung Cancer155, 163–169 (2021).
   PubMed Web of Science ®Google Scholar
• Tam IY , ChungLP, SuenWSet al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin. Cancer Res.12(5), 1647–1653 (2006).
   PubMed Web of Science ®Google Scholar
• Dogan S , ShenR, AngDCet al. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin. Cancer Res.18(22), 6169–6177 (2012).
   PubMed Web of Science ®Google Scholar
• Redig A , ChambersE, LydonC, DahlbergS, AldenR, JanneP. Genomic complexity in KRAS mutant non-small cell lung cancer (NSCLC) from never/light-smokers v smokers. J. Clin. Oncol.34, 9087–9087 (2016).
   Web of Science ®Google Scholar
• Best SA , DingS, KersbergenAet al. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nat. Commun.10(1), 4190 (2019).
   PubMedGoogle Scholar
• Dong ZY , ZhongWZ, ZhangXCet al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin. Cancer Res.23(12), 3012–3024 (2017).
   PubMed Web of Science ®Google Scholar
• Arbour KC , JordanE, KimHRet al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin. Cancer Res.24(2), 334–340 (2018).
   PubMed Web of Science ®Google Scholar
• Skoulidis F , GoldbergME, GreenawaltDMet al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov.8(7), 822–835 (2018).
   PubMed Web of Science ®Google Scholar
• Skoulidis F , HeymachJV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat. Rev. Cancer19(9), 495–509 (2019).
   PubMed Web of Science ®Google Scholar
• Alessi JVM , GlassC, RicciutiB, SpurrLF, ShollLM, AwadMM. Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC). J. Clin. Oncol.38(Suppl. 15), 9577–9577 (2020).
   Web of Science ®Google Scholar
• Alessi JV , RicciutiB, SpurrLFet al. SMARCA4 and Other SWItch/Sucrose NonFermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition. J. Thorac. Oncol.16(7), 1176–1187 (2021).
   PubMed Web of Science ®Google Scholar
• Gao G , LiaoW, MaQ, ZhangB, ChenY, WangY. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma. Lung Cancer149, 41–45 (2020).
   PubMed Web of Science ®Google Scholar
• Pan LN , MaYF, LiZ, HuJA, XuZH. KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer. Cell Biol. Int.45(4), 795–803 (2020).
   Web of Science ®Google Scholar
• Cook JH , MelloniGEM, GulhanDC, ParkPJ, HaigisKM. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat. Commun.12(1), 1808 (2021).
   PubMed Web of Science ®Google Scholar
• West H , CappuzzoF, ReckMet al. 1265P IMpower150: a post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations. Ann. Oncol.31, S817–S818 (2020).
   Google Scholar
• Liu C , ZhengS, JinRet al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett.470, 95–105 (2020).
   PubMed Web of Science ®Google Scholar
• Borghaei H , Paz-AresL, HornLet al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med.373(17), 1627–1639 (2015).
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L , SpiraA, BallingerMet al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet387(10030), 1837–1846 (2016).
   PubMed Web of Science ®Google Scholar
• Rittmeyer A , BarlesiF, WaterkampDet al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet389(10066), 255–265 (2017).
   PubMed Web of Science ®Google Scholar
• Sun L , HsuM, CohenRB, LangerCJ, MamtaniR, AggarwalC. Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer. JAMA Oncol.7(6), 937–939 (2021).
   PubMed Web of Science ®Google Scholar
• Gadgeel S , Rodriguez-AbreuD, FelipEet al. KRAS mutational status and efficacy in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. Ann. Oncol.30, xi64–xi65 (2019).
   Google Scholar
• Sun L , TanM, CohenRB, LangerCJ, MamtaniR, AggarwalC. Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer. JAMA Oncol.7(6), 937–939 (2021).
   PubMed Web of Science ®Google Scholar
• Scheffler M , IhleMA, HeinRet al. K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways. J. Thorac. Oncol.14(4), 606–616 (2019).
   PubMed Web of Science ®Google Scholar
• Skoulidis F , ByersLA, DiaoLet al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov.5(8), 860–877 (2015).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network . Comprehensive molecular profiling of lung adenocarcinoma. Nature511(7511), 543–550 (2014).
   PubMed Web of Science ®Google Scholar
• Imielinski M , BergerAH, HammermanPSet al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell150(6), 1107–1120 (2012).
   PubMed Web of Science ®Google Scholar
• Spranger S , GajewskiTF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer18(3), 139–147 (2018).
   PubMed Web of Science ®Google Scholar
• Quigley D , Silwal-PanditL, DannenfelserRet al. Lymphocyte invasion in IC10/basal-like breast tumors is associated with wild-type TP53. Mol. Cancer Res.13(3), 493–501 (2015).
   PubMed Web of Science ®Google Scholar
• Kerk SA , PapagiannakopoulosT, ShahYM, LyssiotisCA. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat. Rev. Cancer21(8), 510–525 (2021).
   PubMed Web of Science ®Google Scholar
• Yuan TL , AmzallagA, BagniRet al. Differential effector engagement by oncogenic KRAS. Cell Rep.22(7), 1889–1902 (2018).
   PubMed Web of Science ®Google Scholar
• Soundararajan R , FradetteJJ, KonenJMet al. Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy. Cancers (Basel)11(5), 714 (2019).
   PubMed Web of Science ®Google Scholar
• Singh A , DaemenA, NicklesDet al. NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes. Clin. Cancer Res.27(3), 877–888 (2021).
   PubMed Web of Science ®Google Scholar
• Cloer EW , GoldfarbD, SchrankTP, WeissmanBE, MajorMB. NRF2 activation in cancer: from DNA to protein. Cancer Res.79(5), 889 (2019).
   PubMed Web of Science ®Google Scholar
• Jaramillo MC , ZhangDD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev.27(20), 2179–2191 (2013).
   PubMed Web of Science ®Google Scholar
• Best SA , DeSouza DP, KersbergenAet al. Synergy between the KEAP1/NRF2 and PI3K pathways drives non-small-cell lung cancer with an altered immune microenvironment. Cell Metab.27(4), 935–943.e934 (2018).
   PubMed Web of Science ®Google Scholar
• Jordan EJ , KimHR, ArcilaMEet al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov.7(6), 596–609 (2017).
   PubMed Web of Science ®Google Scholar
• Galan-Cobo A , SitthideatphaiboonP, QuXet al. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. Cancer Res.79(13), 3251–3267 (2019).
   PubMed Web of Science ®Google Scholar
• Song S , NguyenV, SchrankTet al. Loss of SWI/SNF chromatin remodeling alters NRF2 signaling in non-small cell lung carcinoma. Mol. Cancer Res.18(12), 1777–1788 (2020).
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I , SchrockAB, KemMet al. Clinicopathologic characteristics of BRG1-deficient NSCLC. J. Thorac. Oncol.15(5), 766–776 (2020).
   PubMed Web of Science ®Google Scholar
• Pore N , WuS, StandiferNet al. Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non-small cell lung cancer and is reversed by STAT3 knockdown. Cancer Discov.11(11), 2828–2845 (2021).
   PubMed Web of Science ®Google Scholar
• Ihle NT , ByersLA, KimESet al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl Cancer Inst.104(3), 228–239 (2012).
   PubMed Web of Science ®Google Scholar
• Arbour KC , RizviH, PlodkowskiAJet al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer. Clin. Cancer Res.27(8), 2209–2215 (2021).
   PubMed Web of Science ®Google Scholar
• Jeanson A , TomasiniP, Souquet-BressandMet al. Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC). J. Thorac. Oncol.14(6), 1095–1101 (2019).
   PubMed Web of Science ®Google Scholar
• Velcheti V , HuX, LiY, El-OstaH, PietanzaMC, BurkeT. Real-world time on treatment with first-line pembrolizumab monotherapy for advanced NSCLC with PD-L1 expression ≥50%: 3-year follow-up data. Cancers (Basel)14(4), 1041 (2022).
   PubMed Web of Science ®Google Scholar
• Ghimessy A , RadeczkyP, LaszloVet al. Current therapy of KRAS-mutant lung cancer. Cancer Metastasis Rev.39(4), 1159–1177 (2020).
   PubMed Web of Science ®Google Scholar
• Liu Z , LiuY, QianLet al. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol. Cell81(19), 4076–4090 (2021).
   PubMed Web of Science ®Google Scholar